Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
复制标题
DOI：
10.1038/pcan.2016.71
复制
发表时间：
2017-06-01
影响因子：
4.8
通讯作者：
Beer, T. M.
中科院分区：
文献类型：
--
作者：
Bryce, A. H.;Alumkal, J. J.;Beer, T. M.
背景：晚期前列腺癌是一种表型多样的疾病，可经历多个临床过程。PSA水平是疾病监测中最广泛使用的参数，但它具有公认的局限性。与临床试验不同，在实践中，临床医生可能仅依靠PSA监测来确定疾病的治疗状态。这种方法还没有经过充分的测试。方法：在PREVAIL研究中，接受雄激素受体抑制剂enzalutamide治疗的转移性去势抵抗性前列腺癌（mCRPC）患者（n = 872）首次化疗，无症状或轻度症状，分析其PSA上升与未上升的情况(经验定义为bbb1.05 vs
BACKGROUND: Advanced prostate cancer is a phenotypically diverse disease that evolves through multiple clinical courses. PSA level is the most widely used parameter for disease monitoring, but it has well-recognized limitations. Unlike in clinical trials, in practice, clinicians may rely on PSA monitoring alone to determine disease status on therapy. This approach has not been adequately tested.METHODS: Chemotherapy-naive asymptomatic or mildly symptomatic men (n = 872) with metastatic castration-resistant prostate cancer (mCRPC) who were treated with the androgen receptor inhibitor enzalutamide in the PREVAIL study were analyzed post hoc for rising versus nonrising PSA (empirically defined as > 1.05 vs